Basilea Pharmaceutica has amended its existing license agreement for Europe, Russia, Turkey and Israel with Pfizer for Basilea’s Cresemba (isavuconazole) to include China—with Hong Kong and Macao—and sixteen countries in the Asia Pacific region. Isavuconazole is an antifungal for the treatment of life-threatening invasive mold infections. Ronald Scott, chief executive officer, Basilea, said, “Cresemba is a well differentiated drug that addresses a critical medical need in patients...